MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 527669 | Name: AG555
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

AG-555 is a small-molecule inhibitor that targets cyclin-dependent kinases (CDKs), interfering with cell cycle progression and exhibiting potential anticancer properties. Structurally, it features a heterocyclic core with functional groups that enhance its binding affinity to the ATP-binding site of CDKs, leading to cell cycle arrest and apoptosis in tumor cells. Its bioavailability and pharmacokinetics make it a promising candidate for further preclinical evaluation in oncology research.

Chemical Structure

AG555
CAS#133550-34-2

Theoretical Analysis

MedKoo Cat#: 527669

Name: AG555

CAS#: 133550-34-2

Chemical Formula: C19H18N2O3

Exact Mass: 322.1317

Molecular Weight: 322.36

Elemental Analysis: C, 70.79; H, 5.63; N, 8.69; O, 14.89

Price and Availability

Size Price Availability Quantity
10mg USD 400.00 2 Weeks
50mg USD 800.00 2 Weeks
100mg USD 1,050.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
AG555; AG 555; AG-555
IUPAC/Chemical Name
(E)-2-Cyano-3-(3,4-dihydroxyphenyl)-N-(3-phenylpropyl)-2-propenamide
InChi Key
GSQOBTOAOGXIFL-LFIBNONCSA-N
InChi Code
InChI=1S/C19H18N2O3/c20-13-16(11-15-8-9-17(22)18(23)12-15)19(24)21-10-4-7-14-5-2-1-3-6-14/h1-3,5-6,8-9,11-12,22-23H,4,7,10H2,(H,21,24)/b16-11+
SMILES Code
O=C(NCCCC1=CC=CC=C1)/C(C#N)=C/C2=CC=C(O)C(O)=C2
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 322.36 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Toda T, Yamamoto S, Yonezawa R, Mori Y, Shimizu S. Inhibitory effects of Tyrphostin AG-related compounds on oxidative stress-sensitive transient receptor potential channel activation. Eur J Pharmacol. 2016 Sep 5;786:19-28. doi: 10.1016/j.ejphar.2016.05.033. Epub 2016 May 26. PMID: 27238971. 2: Wellbrock C, Fischer P, Schartl M. Receptor tyrosine kinase Xmrk mediates proliferation in Xiphophorus melanoma cells. Int J Cancer. 1998 May 4;76(3):437-42. doi: 10.1002/(sici)1097-0215(19980504)76:3<437::aid- ijc24>3.0.co;2-6. PMID: 9579584. 3: Yura Y, Kusaka J, Tsujimoto H, Yoshioka Y, Yoshida H, Sato M. Effects of protein tyrosine kinase inhibitors on the replication of herpes simplex virus and the phosphorylation of viral proteins. Intervirology. 1997;40(1):7-14. doi: 10.1159/000150515. PMID: 9268765. 4: Sion-Vardy N, Vardy D, Rodeck U, Kari C, Levin RM, Malkowicz SB. Antiproliferative effects of tyrosine kinase inhibitors (tyrphostins) on human bladder and renal carcinoma cells. J Surg Res. 1995 Dec;59(6):675-80. doi: 10.1006/jsre.1995.1222. PMID: 8538164. 5: Bhatia R, Munthe HA, Verfaillie CM. Tyrphostin AG957, a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity restores beta1 integrin- mediated adhesion and inhibitory signaling in chronic myelogenous leukemia hematopoietic progenitors. Leukemia. 1998 Nov;12(11):1708-17. doi: 10.1038/sj.leu.2401193. PMID: 9823945. 6: Zhang L, Huang H, Deng L, Chu M, Xu L, Fu J, Zhu Y, Zhang X, Liu S, Zhou Z, Wang Y. TPX2 in malignantly transformed human bronchial epithelial cells by anti-benzo[a]pyrene-7,8-diol-9,10-epoxide. Toxicology. 2008 Oct 30;252(1-3):49-55. doi: 10.1016/j.tox.2008.07.059. Epub 2008 Aug 3. PMID: 18723071. 7: Huang C, Kang TB, Liang NC. Effects of tyrphostins on activity of casein kinase II from rat liver. Zhongguo Yao Li Xue Bao. 1996 Jul;17(4):353-6. PMID: 9812723. 8: Kleinberger-Doron N, Shelah N, Capone R, Gazit A, Levitzki A. Inhibition of Cdk2 activation by selected tyrphostins causes cell cycle arrest at late G1 and S phase. Exp Cell Res. 1998 Jun 15;241(2):340-51. doi: 10.1006/excr.1998.4061. PMID: 9637776. 9: Xia K, Atkins J, Foster C, Armbrust K. Analysis of cyromazine in poultry feed using the QuEChERS method coupled with LC-MS/MS. J Agric Food Chem. 2010 May 26;58(10):5945-9. doi: 10.1021/jf9034282. PMID: 20155910. 10: Ben-Bassat H, Vardi DV, Gazit A, Klaus SN, Chaouat M, Hartzstark Z, Levitzki A. Tyrphostins suppress the growth of psoriatic keratinocytes. Exp Dermatol. 1995 Apr;4(2):82-8. doi: 10.1111/j.1600-0625.1995.tb00227.x. PMID: 7640880. 11: Breinig M, Klein FA, Huber W, Boutros M. A chemical-genetic interaction map of small molecules using high-throughput imaging in cancer cells. Mol Syst Biol. 2015 Dec 23;11(12):846. doi: 10.15252/msb.20156400. PMID: 26700849; PMCID: PMC4704494. 12: Kaur G, Gazit A, Levitzki A, Stowe E, Cooney DA, Sausville EA. Tyrphostin induced growth inhibition: correlation with effect on p210bcr-abl autokinase activity in K562 chronic myelogenous leukemia. Anticancer Drugs. 1994 Apr;5(2):213-22. PMID: 8049505. 13: Seri I, Priel E. The p15 matrix protein of moloney murine leukemia virus is a phosphotyrosine protein. FEBS Lett. 1996 Sep 2;392(3):229-32. doi: 10.1016/0014-5793(96)00820-4. PMID: 8774850. 14: Ben-Bassat H, Rosenbaum-Mitrani S, Hartzstark Z, Levitzki R, Chaouat M, Shlomai Z, Klein BY, Kleinberger-Doron N, Gazit A, Tsvieli R, Levitzki A. Tyrphostins that suppress the growth of human papilloma virus 16-immortalized human keratinocytes. J Pharmacol Exp Ther. 1999 Sep;290(3):1442-57. PMID: 10454524. 15: Seri I, Aflalo E, Gazit A, Priel E. Tyrphostin AG-555 inhibits early and late stages of Moloney murine leukemia virus replication cycle. Int J Oncol. 1997 Jun;10(6):1185-9. doi: 10.3892/ijo.10.6.1185. PMID: 21533502. 16: Esther A, Iftach S, Esther P. Inhibition of Moloney murine leukemia virus replication by tyrphostins, tyrosine kinase inhibitors. FEBS Lett. 1994 Mar 14;341(1):99-103. doi: 10.1016/0014-5793(94)80248-3. PMID: 8137930. 17: Wellbrock C, Geissinger E, Gómez A, Fischer P, Friedrich K, Schartl M. Signalling by the oncogenic receptor tyrosine kinase Xmrk leads to activation of STAT5 in Xiphophorus melanoma. Oncogene. 1998 Jun 11;16(23):3047-56. doi: 10.1038/sj.onc.1201844. PMID: 9662338. 18: Klein BY, Tepper SH, Gal I, Shlomai Z, Ben-Bassat H. Opposing effects of tyrosine kinase inhibitors on mineralization of normal and tumor bone cells. J Cell Biochem. 1997 Jun 1;65(3):420-9. PMID: 9138097. 19: Aflalo E, Iftach S, Segal S, Gazit A, Priel E. Inhibition of topoisomerase I activity by tyrphostin derivatives, protein tyrosine kinase blockers: mechanism of action. Cancer Res. 1994 Oct 1;54(19):5138-42. PMID: 7923131.